Ameloblastoma: Retrospective single institute study and analysis of 86 subjects

The aim of this study was to investigate the results of ameloblastoma treated at a single Cambodian institute during a 6-year period (Jan 2018 – Dec 2023). A retrospective study was designed to include all patients who had been diagnosed with ameloblastoma and treated at the Department of Oral and Maxillofacial Surgery, Preah Ang Duong Hospital, Phnom Penh, Cambodia. Demographic details, location and size of lesion, histological classification of lesion by subtype, radiographic appearance, treatment and recurrence rates for up to 5 years were collated by using patients’ records and the histopathology database. 86 patients were included in the study. 75 (87.2%) were located in the mandible, the most common size of ameloblastoma at presentation was 3.1-6cm in 38 patients (44.2%). By the 2022 WHO Classification of ameloblastomas, conventional ameloblastomas were reported in 55 patients (64%). 11 patients (13%) underwent marsupialisation with 9 patients (60%) having a recurrence within 2 years. 10 patients (12%) underwent enucleation with 6 patients having recurrence within 3 years. 46 patients (53%) underwent radical resection with 6 patients having recurrence within 5 years. 19 patients (22%) declined treatment. Overall, 15/67 treated patients (22.3%) had some form of recurrence in which radical resection had the lowest rate of recurrence.